An Interferon-Free Regimen for Chronic Hepatitis C Virus Infection

Combining a protease inhibitor and a polymerase inhibitor led to declines in viral load, even among patients with previous treatment failure.

In 2011, protease inhibitors will become available for the treatment of chronic hepatitis C virus (HCV) infection. Previous studies have shown that adding one of these agents to peginterferon plus ribavirin improves the rate of sustained virologic response (SVR) but also increases the likelihood of adverse effects and withdrawal (JW Gastroenterol Apr 7 2010 and JW Gastroenterol Aug 20 2010). Now, in the industry-funded INFORM-1 trial, researchers have evaluated the safety, tolerability, and antiviral activity of an interferon-free regimen consisting of two new oral anti-HCV agents: danoprevir (an NS3/4A protease inhibitor) and RG7128 (a nucleoside polymerase inhibitor).

Patients with HCV genotype 1 infection (some treatment naive, some with …

Reviewing Author

Atif Zaman, MD, MPH

Disclosures

Nothing to disclose

Atif Zaman, MD, MPH

Disclosures

Nothing to disclose

An Interferon-Free Regimen for Chronic Hepatitis C Virus Infection

Topics

Reviewing Author